Background

Maintenance of weight is essential for sustenance, well-being and to endorse prolonged life. The prevalence of obesity is increasing at an alarming rate globally, due to modern lifestyle and dietary habits. Endocannabinoids are fatty acid derivatives and numerous studies are carried out which focuses and targets their relationship with obesity, via multiple signals which have been recently known for exerting crucial role in regulating energy balance.

Purpose

This article aims at examining the prospects of endocannabinoids in obesity via directing the role of ECs in stimulating hunger.

Result

In last few years, irregular stimulation of endocannabinoid system has been suggested as a chief element in the progression of obesity-associated metabolic complications. Certainly, this cascade system comprises of cannabinoid type1 and 2 receptors (CB1R and CB2R) along with their endogenous lipid ligands which are responsible for enhanced feeding behavior as well as lipid metabolism. Significantly, inhibiting CB1R activity might reduce metabolic abnormality linked with obesity.

Conclusion

Conclusion withdrawn on the basis of supporting scientific data and evidences report that the blockade of cannabinoids can serve as a therapeutic potential for treatment of obesity. Future prospective aims at assessing molecular pathways which contributes towards ECS, elicited weight control and to evaluate how these mechanisms are presently relocated into the production of novel cannabinoid drugs exhibiting enriched care.

中文翻译：

---

了解内源性大麻素系统在肥胖中的可能作用

 背景

维持体重对于维持生计、健康和延长寿命至关重要。由于现代生活方式和饮食习惯，肥胖症的患病率在全球范围内以惊人的速度增加。内源性大麻素是脂肪酸衍生物，许多研究通过最近已知在调节能量平衡中发挥关键作用的多种信号来关注和针对其与肥胖的关系。

 目的

本文旨在通过指导 EC 在刺激饥饿方面的作用来研究内源性大麻素在肥胖中的前景。

 结果

在过去几年中，内源性大麻素系统的不规则刺激被认为是肥胖相关代谢并发症进展的主要因素。当然，这个级联系统由 1 型和 2 型大麻素受体（CB1R 和 CB2R）及其内源性脂质配体组成，这些配体负责增强摄食行为和脂质代谢。值得注意的是，抑制 CB1R 活性可能会减少与肥胖相关的代谢异常。

 结论

基于科学数据和证据的支持而撤回的结论表明，大麻素的阻断可以作为治疗肥胖症的治疗潜力。未来的前景旨在评估有助于 ECS、引发体重控制的分子途径，并评估这些机制目前如何重新定位到表现出丰富护理的新型大麻素药物的生产中。